ArticleJournal of ethnopharmacology2015
An extract of Artemisia dracunculus L. stimulates insulin secretion from β cells, activates AMPK and suppresses inflammation.
Article in Journal of ethnopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- AqueousPharmaceutics · 2026Article
- Astragalin Exerted Hypoglycemic Effect by Both Inhibiting α-Glucosidase and Modulating AMPK Signaling Pathway.Nutrients · 2025Article
- UPLC-ESI-QTOF-MS Profiling of Phenolic Compounds fromMolecules (Basel, Switzerland) · 2022Article
- Bioactive compounds from Artemisia dracunculus L. activate AMPK signaling in skeletal muscle.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Possible Synergistic Antidiabetic Effects of QuantifiedBiology · 2021Article
- Herbal Medicines Targeting the ImprovedEvidence-based complementary and alternative medicine : eCAM · 2021Review
- Protective effects of Artemisia judaica extract compared to metformin against hepatorenal injury in high-fat diet/streptozotocine-induced diabetic rats.Environmental science and pollution research international · 2020Article
- Capsaicin Analogues Derived fromNutrients · 2019Article
- An Extract ofOxidative medicine and cellular longevity · 2018Article
- An Overview of Herbal Products and Secondary Metabolites Used for Management of Type Two Diabetes.Frontiers in pharmacology · 2017Review
- Natural Products to Counteract the Epidemic of Cardiovascular and Metabolic Disorders.Molecules (Basel, Switzerland) · 2016Review
- Protective Action of Carica papaya on β-Cells in Streptozotocin-Induced Diabetic Rats.International journal of environmental research and public health · 2016Article
- Aqueous and alcoholic extracts ofAvicenna journal of phytomedicineArticle
- Influence of Flavonoids on Mechanism of Modulation of Insulin Secretion.Pharmacognosy magazineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
ethnopharmacological relevanceArtemisia dracunculus L. (Russian tarragon) is a perennial herb belonging to the family Compositae and has a history of medicinal use in humans, particularly for treatment of diabetes. AIM OF THE STUDY: In this study a defined plant extract from A. dracunculus L. (termed PMI-5011) is used to improve beta(β) cells function and maintain β cell number in pancreatic islets as an alternative drug approach for successful treatment of diabetes. MATERIALS AND
methodsMouse and human pancreatic beta cells were treated with defined plant extract of A. dracunculus L. (PMI-5011) to understand the mechanism(s) that influence beta cell function and β cell number.
resultsWe found that the PMI-5011 enhances insulin release from primary β cells, isolated mouse and human islets and it maintains β cell number. Insulin released by PMI-5011 is associated with the activation of AMP-activated protein kinase (AMPK), and protein kinase B (PKB). Furthermore, PMI-5011 suppresses LPS/INFγ-induced inflammation and inflammatory mediator(s) in macrophages. PMI-5011 inhibited Nitric oxide (NO) production and expression of inducible nitric oxide synthase (iNOS) at the protein level and also attenuated pro-inflammatory cytokine (IL-6) production in macrophages.
conclusionPMI-5011 has potential therapeutic value for diabetes treatment via increasing insulin release from β cells and decreases capacity of macrophages to combat inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.